Evidence map›Paper›PMID 26093059›Full record

ReviewCurrent opinion in structural biology2015

Conceptual and methodological advances in cell-free directed evolution.

Igor Dodevski, George C Markou, Casim A Sarkar

Abstract readReview
In one paragraph

Review in Current opinion in structural biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Bottom-Up Synthetic Biology Using Cell-Free Protein Synthesis.Advances in biochemical engineering/biotechnology · 2023
    Review
  4. Progresses in Cell-Free In Vitro Evolution.Advances in biochemical engineering/biotechnology · 2023
    Review
  5. Advancing synthetic biology through cell-free protein synthesis.Computational and structural biotechnology journal · 2023
    Review
  6. Article
  7. Review
  8. Flexible Proteins at the Origin of Life.Life (Basel, Switzerland) · 2017
    Article
  9. Bacterial cell-free expression technology toSynthetic and systems biotechnology · 2017
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Igor DodevskiDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455, USA.
George C MarkouDepartment of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA.
Casim A SarkarDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455, USA; Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: csarkar@umn.edu.

Funding

De novo engineering of protein agonists and antagonistsR21CA179180 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SARKAR, CASIM · 2013 to 2014
$360k
NCI NIH HHS CA179180NCI NIH HHS R21 CA179180
6 · The paper itself

Abstract

Although cell-free directed evolution methods have been used to engineer proteins for nearly two decades, selections on more complex phenotypes have largely remained in the domain of cell-based engineering approaches. Here, we review recent conceptual advances that now enable in vitro display of multimeric proteins, integral membrane proteins, and proteins with an expanded amino acid repertoire. Additionally, we discuss methodological improvements that have enhanced the accessibility, efficiency, and robustness of cell-free approaches. Coupling these advances with the in vitro advantages of creating exceptionally large libraries and precisely controlling all experimental conditions, cell-free directed evolution is poised to contribute significantly to our understanding and engineering of more complex protein phenotypes.

Indexed as

Directed Molecular EvolutionProtein EngineeringAmino AcidsMembrane ProteinsPhenotypeProteinsAmino AcidsMembrane ProteinsProteins

Identifiers

PMID26093059
PMCPMC4641812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.